Institutional members access full text with Ovid®

The Efficacy of Fenofibrate is in Question

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: March 2012 - Volume 112 - Issue 3 - p 24
doi: 10.1097/01.NAJ.0000412634.70645.1e
Drug Watch

* The Food and Drug Administration is requiring the manufacturer of fenofibric acid (Trilipix), also called fenofibrate, to complete a clinical trial to determine the drug's efficacy in reducing cardiovascular events in patients with type 2 diabetes who are already taking a statin.

* This decision follows the outcome of a clinical trial that found that the combination of fenofibric acid and simvastatin (Zocor) was no better than simvastatin alone in minimizing cardiovascular risk.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.